Integration of single cell omics with biobank data discovers trans effects of SREBF1 abdominal obesity risk variants on adipocyte expression of more than 100 genes

Mihir G. Sukhatme; Asha Kar; Uma Thanigai Arasu; Seung Hyuk T. Lee; Marcus Alvarez; Kristina M. Garske; Kyla Z. Gelev; Sandhya Rajkumar; Sankha Subhra Das; Dorota Kaminska; Ville Männistö; Hilkka Peltoniemi; Sini Heinonen; Ulla Säiläkivi; Tuure Saarinen; Anne Juuti; Kirsi H. Pietiläinen; Jussi Pihlajamäki; Minna U. Kaikkonen; Päivi Pajukanta

doi:10.1101/2024.11.22.24317804

Abstract

Given the fast-increasing prevalence of obesity and its comorbidities, it would be critical to improve our understanding of the cell-type level differences between the two key human adipose tissue depots, subcutaneous (SAT) and visceral adipose tissue (VAT), in their depot-specific contributions to cardiometabolic health. We integrated cell-type level RNA- and ATAC-seq data from human SAT and VAT biopsies and cell-lines to comprehensively elucidate transcriptomic, epigenetic, and genetic differences between the two fat depots. We identify cell-type marker genes for tissue specificity and functional enrichment, and show through genome-wide association study (GWAS) and partitioned polygenic risk score (PRS) enrichment analyses that the marker genes upregulated in SAT adipocytes have more prominent roles in abdominal obesity than those of VAT. We also identify SREBF1, a master transcription factor (TF) of fatty acid synthesis and adipogenesis, as specifically upregulated in SAT adipocytes and present in numerous SAT functional pathways. By integrating multi-omics data from an independent human cohort, we further show that the risk allele carrier status of seven abdominal obesity GWAS variants in the cis region of SREBF1 affects the adipocyte expression of 146 SAT adipocyte marker genes in trans. We replicate this finding independently in the UK Biobank by showing that the partitioned abdominal obesity PRSs of the trans gene sets differ by the regional SREBF1 risk allele carrier status. In summary, we discover the master TF, SREBF1, driving the SAT adipocyte expression profiles of more than a hundred of adipocyte marker genes in trans, a finding that indicates that human trans genes can be identified by integrating single cell omics with biobank data.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by NIH grants R01HL170604 (PP) and R01DK132775 (PP), the Academy of Finland (272376, 266286, 314383, 335443, KHP; 314457 AJ: 338417 SH; and 333021, 335973, MUK), Finnish Medical Foundation (KHP, AJ), Finnish Diabetes Research Foundation (SH, KHP), Orion Foundation (SH), Novo Nordisk Foundation (NNF10OC1013354, NNF17OC0027232, NNF20OC0060547, KHP), Paulo Foundation (SH, KHP), Gyllenberg Foundation (KHP), Sigrid Juselius Foundation (KHP, MUK), Paavo Nurmi Foundation (SH), Helsinki University Hospital Research Funds (SH, KHP, AJ) and the University of Helsinki (KHP). This research was partly supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant 802825 to MUK), and the Finnish Foundation for Cardiovascular Research (MUK).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Hospital Ethics Committee of Helsinki University gave ethical approval for the RYSA study. The Ethics Committee of the Northern Savo Hospital District gave ethical approval for KOBS. The North West Multi-centre Research Ethics Committee gave ethical approval for the UKB study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data availability statement

The data that support the findings in this manuscript are available from the UK Biobank. However, restrictions apply to the availability of these data, which were used in this study under UK Biobank Application number 33934. UK Biobank data are available for bona fide researchers through the application process: https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us. The KOBS VAT snRNA-seq will be made available in the NIH Gene Expression Omnibus (GEO) upon acceptance, under accession number GSEXX. The KOBS SAT snRNA-seq data were made previously available in GEO, under accession number GSE269926. The RYSA SAT snRNA-seq data will be made available in GEO under accession number GSE274778. The data from the primary human preadipocyte differentiation experiment were previously made available in GEO, under accession number GSE249195 for the RNA and GSE269926 for the ATAC. The SAT and VAT snRNA-seq data described in Emont et al.³⁴ can be found in the Single Cell Portal under study number SCP1376.